Evaluation of Alternations Lncrna Cacs2 Expression in the T98g Glioblastoma Cell Line Under Treatment With Thiosemicarbazones Complexes (Cu)

Background and aim: brain cancer or brain tumor is an abnormal growth of the brain or is a type of hard intracranial neoplasm and intracerebral or central canal of the spinal cord, which may be benign or malignant. glioblastoma multiforme is the most common and malignant primary brain tumor and usually occurs in the 6th to 7th decades thiosemicarbazones complexes are compounds with a long history and a wide range of biological properties including anticancer, antibacterial and anti-malarial effects. currently, the main known effects associated with their anticancer activity include: reactive oxygen production (ros), topoisomerase ii inhibition, and more recently inhibition of multiple drug resistance protein (mdr1). the purpose of this study was to evaluation of alternations lncrna cacs2 expression in the t98g glioblastoma cell line under treatment with thiosemicarbazones complexes(cu)methods: in this study, thiosemicarbazones complexes(cu) were prepared with 17.5 and 20 µm concentrations. the adenocarcinoma t98g cell line was treated by cu in these groups after cell passage. then rna extraction and cdna synthesis were performed and the expression of lncrna cacs2 in the pi3 kinase / akt signaling pathway and gapdh gene as the housekeeping gene were evaluated by real time pcr. statistical analysis was performed.results: our results confirmed that, at both concentrations of 17.5 and 20 µm a considerable gene expression increased observed after 24 hours treatment.at 17.5 and 20µm concentrations, expression was detected 0.564 and 0.234 fold respectively.conclusion: the results of trials related to thiosemicarbazones complexes cu and comparison with control drug showed that cu can be effective in increasing lncrna cacs2 expression as a tumor suppressor.